Clinical Pathway for Pancreatic Enzyme Replacement Therapy (PERT) in Children with or at Risk for Exocrine Pancreatic Insufficiency (EPI)
Clinical Pathway for Pancreatic Enzyme Replacement Therapy (PERT) in Children with or at Risk for Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)
EPI is common in children who have CF and affects approximately 85% of the CF population. EPI is common in patients who have CF and affects approximately 85% of the CF population.
Clinical Presentation
Infants/children with CF and EPI symptoms may be admitted to the hospital because they present with the following:
Symptoms/Signs | PERT Initiation |
---|---|
|
|
|
|
|
|
Considerations for PERT initiation
- Enzymes may be initiated in the inpatient and outpatient environment before EPI testing
- Contact CF Nutritionist for further dosing guidance as needed
- Initiate PERT:
Testing
EPI testing is obtained based on clinical signs and symptoms or confirmed diagnosis of CF.